Zymeworks is a Canadian biotechnology company based in Vancouver, British Columbia. The company develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases.
History
In 2011, Merck entered an agreement with Zymeworks to use their Azymetric™ platform for the development and commercialization of bispecific antibodies against targets in multiple therapeutic fields.[1] The arrangement involved the joint development and improvement of the platform, as well as Merck taking the resulting novel antibody products through clinical development.[2]
Organization
Lumira Ventures is an investor in Zymeworks.[3]
External links
Merck & Co. Seals Bispecific Antibody Collaboration with Zymeworks. (2011, August 29). GEN - Genetic Engineering and Biotechnology News. http://archive.today/2022.04.28-152140/https://www.genengnews.com/topics/drug-discovery/merck-co-seals-bispecific-antibody-collaboration-with-zymeworks/ ↩︎
FOI Request - HTH-2015-51828. (2016, February 12). Government of British Columbia. https://web.archive.org/web/20220428045844/http://docs.openinfo.gov.bc.ca/Response_Package_HTH-2015-51828.pdf ↩︎
Portfolio. Lumira. Retrieved March 26, 2023, from https://web.archive.org/web/20230326213612/https://www.lumiraventures.com/portfolio-companies/ ↩︎
